Beam Therapeutics Inc. Common Stock BEAM

Beam Therapeutics Inc. es una empresa de biotecnología dedicada a proporcionar curas de por vida a pacientes que sufren de enfermedades graves. La Compañía opera una plataforma totalmente integrada para medicamentos genéticos de precisión. Su tecnología de edición de bases permite una clase diferenciada de medicamentos genéticos de precisión que apuntan a una sola base en el genoma sin causar una rotura de doble cadena en el ácido desoxirribonucleico (ADN). La Compañía está avanzando con su tecnología de edición de bases en tres carteras de enfermedades: hematología, inmunología/oncología y enfermedades genéticas. Sus programas en etapa clínica incluyen BEAM-101, BEAM-201, BEAM-301 y BEAM-302. BEAM-101 es una terapia de investigación específica para el paciente, autóloga de células madre hematopoyéticas (HSC), diseñada para ofrecer un perfil que incorpora ediciones de bases que pretenden imitar polimorfismos de un solo nucleótido vistos en individuos con persistencia hereditaria de hemoglobina fetal (HPFH). BEAM-201 es un candidato en desarrollo compuesto por células T.

• The Motley Fool 22 sept

  Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  Cathie Wood's Ark Invest added to positions in Meta Platforms, Airbnb, and Beam Therapeutics on Monday. Meta surged 11% on momentum from its new Muse AI app and an upgraded price target from Wells Fargo. Airbnb continues strong revenue growth despite headwinds from rising travel costs and regulatory scrutiny. Beam Therapeutics is recovering after recent clinical trial data showed efficacy in its gene-editing treatment for alpha-1 antitrypsin deficiency.

  

• GlobeNewswire Inc. 31 ago

  Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

  Beam Therapeutics announced management participation in three major investor conferences in September 2026. The company also reported progress on its BEAM-302 trial in Alpha-1 Antitrypsin Deficiency, with dosing completed for adult and adolescent patients and updated data selected for presentation at the European Respiratory Society Congress 2026.

  

• GlobeNewswire Inc. 25 ago

  As Sickle Cell Innovation Accelerates, Hematologists Signal Demand for a Broader Treatment Arsenal Beyond Gene Therapy

  Hematologists increasingly favor a diverse sickle cell disease treatment landscape combining gene therapies with oral disease-modifying agents. Mitapivat (Agios) surged to the most desired pipeline therapy at 24% physician preference, while BEAM-101 (Beam Therapeutics) and etavopivat (Novo Nordisk) also gained traction. Despite innovation, 70% of hematologists rate unmet need as high, with 51% of SCD patients not optimally managed with current treatments.

  

• The Motley Fool 20 jul

  Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

  Cathie Wood's Ark Invest has significantly increased its position in Beam Therapeutics, a biotech company using base editing technology for genetic treatments. With multiple clinical programs advancing toward FDA approval and sufficient cash runway through mid-2029, Beam could transform into a commercial biotech company. However, the investment remains speculative and dependent on successful clinical trials and regulatory approvals.

  

• GlobeNewswire Inc. 3 jul

  Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast

  The global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety concerns remain significant challenges.